ADCT - The Buzz Show: ADC Therapeutics (NYSE: ADCT) Agreement with HealthCare Royalty Partners

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ADC Therapeutics  Enters Financing Agreement with HealthCare Royalty Partners”

ADC Therapeutics SA (NYSE: ADCT) climbed 7% from its previous close in early morning trading after the company announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners.

Under the terms of the financing agreement, ADC Therapeutics will receive $225 million upon closing, and is eligible to receive an additional $75 million upon the first commercial sale of ZYNLONTATM in Europe and a further $25 million upon the achievement of a near-term commercial milestone for ZYNLONTA.

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

For more information, please visit: ADC Therapeutics SA

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: ADC Therapeutics (NYSE: ADCT) Agreement with HealthCare Royalty Partners first appeared on Financial Buzz .

For further details see: